Figure 6 (Eylea 01)
Eylea Injection, Solution
Product Images NDC 61755-005
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Eylea (NDC 61755-005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Regeneron Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Eylea 01a)
This is a description of various parts of a syringe including a syringe cap, Luer lock, 0.05 ml dosing line, plunger, finger grip, and plunger rod.*
Figure 2 (Eylea 01b)
Figure 3 (Eylea 01c)
Figure 4 (Eylea 01d)
Figure 5a (Eylea 01e)
Figure 5b (Eylea 01f)
Figure 7 (Eylea 02)
Figure 8 (Eylea 03)
Figure 9a (Eylea 04)
Figure 9b (Eylea 04a)
Figure 10 (Eylea 05)
Figure 11 (Eylea 06)
Figure 12a (Eylea 07)
Figure 12b (Eylea 07a)
Figure 13 (Eylea 08)
Mean change in visual acuity is being measured over a period of up to 96 weeks for multiple treatments including EYLEA at 2mg quantity every 8 or 4 weeks, as well as Ranibizumab at 0.5mg every 4 weeks. Visual acuity is measured in letters and recorded at various timepoints throughout the study.*
Figure 14 (Eylea 09)
Figure 15 (Eylea 10)
This appears to be a chart or graph showing the mean change in visual acuity in letters after 4, 8, 12, 16, 20, and 24 weeks for a group of patients who received EYLEA 2 mg Q4 weeks and a control group. The numbers on the left and right probably indicate visual acuity scores, and the plus signs and numerical values likely indicate the change in scores from the baseline.*
Figure 16 (Eylea 11)
The text describes a comparison study of the mean change in visual acuity over weeks, between a group receiving EYLEA 2mg every 8 weeks and another group receiving it every 4 weeks. There are also two columns of letters next to the visual acuity data, but there is no information about them.*
Figure 17 (Eylea 11a)
Not-Available*
Principal Display Panel (2 mg/0.05 mL Vial Carton)
EYLEA is a medication used for intravitreal injection. It is supplied in a single-use vial and comes with a plastic syringe, two needles and a package insert. The medication contains the active ingredient aflibercept and has a strength of 2mg/0.05.*
Principal Display Panel (2 mg/0.05 mL Syringe Carton)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
